TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sutro Biopharma ( (STRO) ) just unveiled an announcement.
On June 6, 2025, Sutro Biopharma held its 2025 Annual Meeting of Stockholders, where several key proposals were adopted. These included the election of three Class I directors to serve until 2028, the ratification of Ernst & Young LLP as the independent accounting firm for 2025, approval of executive compensation on a non-binding basis, and an amendment to the company’s Restated Certificate of Incorporation to potentially enact a reverse stock split.
The most recent analyst rating on (STRO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Neutral.
Sutro Biopharma’s score is driven primarily by significant financial challenges and a bearish technical outlook. The strategic review and leadership change add uncertainty, but they may offer a path towards improved operations. The valuation remains weak given the negative earnings and lack of dividend yield, which are key considerations for investors.
To see Spark’s full report on STRO stock, click here.
More about Sutro Biopharma
Average Trading Volume: 1,867,766
Technical Sentiment Signal: Sell
Current Market Cap: $71.62M
For detailed information about STRO stock, go to TipRanks’ Stock Analysis page.